Ketamine Infusion for Treatment-Resistant Depression: Evidence Review

The Ketamine Revolution in Depression Treatment

Ketamine has emerged as a groundbreaking treatment for depression, particularly for patients who have not responded to conventional antidepressants. Unlike SSRIs and SNRIs that take 4-6 weeks to show effects, ketamine can produce antidepressant responses within hours of administration.

This rapid onset of action represents a paradigm shift in psychiatry. For patients with severe, treatment-resistant depression (TRD) — defined as failure to respond to two or more adequate antidepressant trials — ketamine offers hope where other treatments have failed.

How Ketamine Works

Ketamine's antidepressant mechanism differs fundamentally from traditional antidepressants:

Glutamate Pathway

Rather than targeting serotonin, ketamine acts on the glutamate system — the brain's primary excitatory neurotransmitter. Specifically, it blocks NMDA receptors, triggering a cascade of downstream effects:

AMPA receptor activation — Increased glutamate signaling through alternative receptors

BDNF release — Brain-derived neurotrophic factor promotes synaptic growth

mTOR pathway activation — Rapid formation of new synaptic connections

Synaptogenesis — Restoration of synapses lost during chronic stress and depression

This mechanism explains the rapid onset: while SSRIs slowly increase serotonin availability, ketamine directly stimulates the growth of new neural connections.

Clinical Evidence

IV Ketamine Infusions

The standard IV ketamine protocol involves:

Dose: 0.5 mg/kg administered over 40 minutes

Frequency: 2-3 sessions per week for 2-3 weeks (induction phase)

Maintenance: Monthly or as-needed booster infusions

Studies from the PsiHub database show:

Response rate: 50-70% of TRD patients show significant improvement

Onset: Effects often noticeable within 2-4 hours

Duration: Single infusion effects last 3-7 days on average

Remission: Approximately 30% achieve full remission during induction

Esketamine (Spravato)

The FDA approved esketamine (the S-enantiomer of ketamine) as a nasal spray in 2019. Key differences from IV ketamine:

Administered as a nasal spray under medical supervision

FDA-approved specifically for TRD and major depressive disorder with suicidal ideation

Must be administered in a certified healthcare facility (REMS program)

Insurance coverage is more widely available

Comparing Ketamine to Other Psychedelics

How does ketamine compare to other psychedelic-assisted therapies?

| Factor | Ketamine | Psilocybin | MDMA | |--------|----------|------------|------| | Legal status | FDA-approved | Investigational | Investigational | | Sessions needed | Multiple ongoing | 1-3 | 2-3 | | Onset of action | Hours | Days | Days-weeks | | Duration of effect | Days-weeks | Weeks-months | Months | | Primary mechanism | Glutamate/NMDA | Serotonin/5-HT2A | Serotonin/oxytocin |

Explore detailed comparisons on PsiHub's substance profiles.

Risks and Side Effects

Ketamine treatment carries specific risks:

Dissociative effects — Temporary feelings of detachment from body and surroundings

Elevated blood pressure — Requires monitoring during infusions

Nausea and dizziness — Common but usually transient

Abuse potential — Schedule III controlled substance with known recreational abuse

Bladder toxicity — Associated with chronic, high-dose recreational use (not clinical doses)

Cognitive effects — Temporary impairment during and shortly after administration

Cost and Access

A significant barrier to ketamine treatment is cost:

IV ketamine infusions: $400-800 per session (often not covered by insurance)

Esketamine (Spravato): Covered by many insurance plans but requires REMS certification

A typical induction course of 6 IV infusions may cost $2,400-4,800 out of pocket

Future Directions

Research continues on ketamine-related compounds that may offer similar benefits with fewer side effects, including arketamine (R-ketamine) and other NMDA modulators. Explore the latest research on PsiHub.

References

Krystal, J.H. et al. (2019). Ketamine: A paradigm shift for depression research. Neuron.

Daly, E.J. et al. (2019). Efficacy of Esketamine Nasal Spray. JAMA Psychiatry.

Explore ketamine studies on PsiHub